Ebrahimi A, Mehrabi M, Miraghaee SS, Mohammadi P, Kafash FF, Delfani M, et al
Tirzepatide Side Effects# Well-characterized from Phase 3 (SURPASS, SURMOUNT) trials and post-market surveillance: Gastrointestinal : Nausea (12-33%), diarrhea (12-21%), vomiting (5-12%), constipation (6-11%) Decreased appetite : Common and expected pharmacological effect Injection site reactions : Mild, occurring in 2-5% of patients Pancreatitis : Rare
Whats frustrating about this conversation is that the loudest voices condemning peptides often come from the same systems that benefit from people believing there are no safe, affordable alternatives
Remember, liquids are always great options if you cant swallow capsules